Just over one third of invasive Escherichia coli samples collected from patients with bloodstream infections across 26 countries were resistant to multiple classes of antibiotics, according to a global analysis published in Clinical Infectious Diseases.
Researchers examined 10,098 extraintestinal pathogenic E. coli isolates collected between 2011 and 2023 and classified 34% as multidrug resistant. Resistance rates varied dramatically by country, from 83.3% in India, 76.6% in Mexico, and 69.4% in China to 12.1% in the Netherlands, 11.6% in New Zealand, and 10.6% in Sweden. Countries with lower income levels generally had higher rates.
The everyday relevance is that E. coli is not an exotic organism. It lives in the intestines of healthy people, causes the majority of urinary tract infections, and is a leading cause of bloodstream infection in older adults. When it moves out of the gut and resistance limits the drugs that work, an ordinary infection becomes a hospital admission.
The Difference Between Gut E. Coli and Invasive Disease
Most people encounter E. coli as either a normal intestinal resident or as the cause of foodborne illness with diarrhea. Invasive E. coli disease is a different clinical problem.
It occurs when the bacteria reach normally sterile sites, most often the bloodstream, and can also involve other organs. From there it can progress to sepsis, a life-threatening response to infection that causes organ dysfunction. The most common route is an ascending urinary tract infection that reaches the kidney and then the blood.
Study authors noted that resistance to carbapenems, third-generation cephalosporins, aminoglycosides, or fluoroquinolones is an obstacle to successful treatment of invasive E. coli disease. The CDC classifies antimicrobial resistance as an urgent global public health threat. Those are the drug classes clinicians reach for when an infection is serious.
Resistance matters most in the first hours. A patient with sepsis is started on empiric antibiotics before laboratory results identify the organism and its susceptibilities. If the initial choice does not cover a resistant strain, effective treatment is delayed at the point when delay is most dangerous.
The Clones and Serotypes Driving the Pattern
The analysis found serotypes O25, O2, O6, and O1 were the most prevalent overall. Among multidrug-resistant isolates, O25 was the most common in every country studied, ranging from 11.3% in China to 56.2% in Mexico.
One sequence type stood out. ST131, a globally dominant clone and an important cause of urinary tract and bloodstream infections worldwide, accounted for 33% of all multidrug-resistant isolates. Tracking that clone is one reason the authors argue for continued epidemiological monitoring of high-risk lineages.
The findings were summarized by CIDRAP, which reported the study's conclusion that ongoing research into preventive and therapeutic strategies, including vaccines, is needed to reduce the burden of bacterial disease and limit resistance.
Reading the Numbers Carefully
Two limits deserve attention before anyone extrapolates the 34% figure to their own hospital.
First, funding and affiliation. The study was conducted by researchers with the drugmaker Johnson and Johnson, which has an interest in vaccine development against extraintestinal pathogenic E. coli. That does not make the surveillance data wrong, and the isolates and laboratory methods are objective, but readers should know who produced the analysis and why. Company-affiliated research warrants the same scrutiny as any other.
Second, generalizability. As CIDRAP's antimicrobial stewardship coverage notes, resistance patterns differ sharply between health systems. This is a global surveillance dataset spanning 26 countries and 12 years. National rates differ by an order of magnitude between the highest and lowest countries, which means the pooled figure describes no individual country well. The United States was not among the highest-rate countries reported, and US patterns are tracked separately by CDC and by hospital antibiograms.
Isolate collections also reflect which laboratories participate and which patients get cultured, so surveillance samples are not a random draw from all infections. The 12-year collection window also spans a period during which resistance patterns shifted, so a single pooled percentage compresses real change over time.
Reducing Risk Without Overreacting
Nothing here calls for changes in ordinary household behavior beyond what already reduces infection risk.
Your own hospital's antibiogram, a local summary of which organisms are resistant to which drugs, is a far better guide to regional risk than any global figure. Ask your clinician about it if you have had repeated infections.
The people at highest risk of invasive E. coli disease are older adults, people with urinary catheters, people with recurrent urinary tract infections, those with kidney stones or urinary obstruction, people with diabetes, and those with weakened immune systems. Recent hospitalization, recent antibiotic use, and international travel to regions with high resistance rates all increase the chance that a resistant strain is involved.
Urinary symptoms that warrant prompt attention include burning with urination, urgency, and lower abdominal discomfort. Signs that an infection may have become more serious include fever with shaking chills, flank or back pain, confusion or sudden disorientation in an older adult, rapid breathing, and lightheadedness. Those warrant urgent evaluation rather than waiting.
Ask for a urine culture when an infection is being treated, particularly with recurrent infections. Culture results tell your clinician which antibiotic will actually work and are the reason resistance is detected at all.
Take antibiotics only when prescribed and complete the course as directed. Do not use leftover antibiotics or antibiotics prescribed for someone else. Do not press for antibiotics for viral illness. Each unnecessary course selects for resistant organisms in your own body.
If you have had recent care abroad or have been hospitalized recently, tell your clinician. That history can change the initial antibiotic choice.
Frequently Asked Questions
What did the analysis find? Of 10,098 invasive E. coli isolates from 26 countries collected between 2011 and 2023, 34% were multidrug resistant, with wide variation by country.
What is invasive E. coli disease? Infection that occurs when E. coli spreads beyond the intestines into normally sterile sites such as the bloodstream, where it can cause sepsis.
Does this apply to the United States? Not directly. Rates ranged from about 11% to over 83% by country. US patterns are tracked separately by CDC and by individual hospital antibiograms.
Who funded the study? It was conducted by researchers with the drugmaker Johnson and Johnson, which is pursuing vaccine development in this area.
Who is at highest risk? Older adults, people with urinary catheters or recurrent urinary infections, those with diabetes or weakened immune systems, and people recently hospitalized or treated abroad.
What symptoms should prompt urgent care? Fever with shaking chills, flank or back pain, sudden confusion in an older adult, rapid breathing, or lightheadedness alongside urinary symptoms.
How can I help slow resistance? Take antibiotics only as prescribed, complete the course, never use leftover or someone else's antibiotics, and ask for a culture when appropriate.
